2023 Early Hearing Detection & Intervention Conference
March 5-7, 2023 • Cincinnati, OH
10/28/2018 | 9:30 AM - 10:30 AM | Can Acquired Auditory Neuropathy Spectrum Disorder (ANSD) be Linked to Malaria and/or Quinine Treatment? | Kramer Lecture Theater 2
Can Acquired Auditory Neuropathy Spectrum Disorder (ANSD) be Linked to Malaria and/or Quinine Treatment?
Malaria is a known cause of hearing loss, and quinine is known to be ototoxic, however no literature has been identified that links either with auditory neuropathy spectrum disorder (ANSD).
Two case studies are presented of Malawian children who acquired ANSD following severe malaria which was treated with quinine.
Both children presented with bilateral reverse-slope sensorineural hearing loss with robust otoacoustic emissions and absent auditory brainstem response. Prior to malarial infection, neither had any reported health or hearing problems, nor was there a family history of hereditary neuropathy or hearing loss.
In areas where malaria is endemic, it is important to be aware of the possibility of acquired ANSD. Otoacoustic emissions should be a routine component of hearing assessment, and ANSD should be considered whenever a patient reports hearing problems, irrespective of pure tone audiometry results.
- To be aware of acquired ANSD in areas of endemic malaria
- To understand the pattern of initial test results that indicates acquired ANSD
- To know how to confirm a case of ANSD
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Miss H Brough
(), African Bible College Hearing Clinic and Training Centre (ABC HCTC), Lilongwe, Malawi, helenbrough@africanbiblecolleges.net;
Helen trained as a clinical scientist in Audiology in Cambridge, England. She was clinical lead at ABC Hearing Clinic for 12 months in 2016-17, and continues to be a part-time lecturer at the college. She currently works in clinical practice in London.
ASHA DISCLOSURE:
Financial -
Nonfinancial -